CAS 413599-62-9

4-Quinazolinamine,N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-

Description:

4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]- is a synthetic organic compound characterized by its complex structure, which includes a quinazoline core, a brominated and fluorinated phenyl group, and a triazole moiety. This compound typically exhibits properties such as moderate solubility in organic solvents and potential bioactivity, making it of interest in medicinal chemistry, particularly in the development of pharmaceuticals. The presence of the quinazoline ring suggests potential applications in targeting various biological pathways, while the triazole group may enhance its pharmacological profile. The specific halogen substitutions (bromo and fluoro) can influence the compound's reactivity, stability, and interaction with biological targets. Overall, this compound represents a class of heterocyclic compounds that are often explored for their therapeutic potential, particularly in oncology and infectious disease research. Further studies would be necessary to elucidate its specific biological activities and mechanisms of action.

Formula: C₁₉H₁₆BrFN₆O₂

ZD-4190

CAS: 413599-62-9

ZD-4190

Purity: ≥98%

Molecular weight: 459.27g/mol

Ref: 54-BUP09053

ZD-4190

CAS: 413599-62-9

ZD-4190 blocks VEGFR2 and EGFR, aiding cancer treatment.

Formula: C₁₉H₁₆BrFN₆O₂

Purity: 99.12%

Color and Shape: Solid

Molecular weight: 459.27

Ref: TM-T5475

ZD-4190

CAS: 413599-62-9

ZD-4190 is a small molecule that blocks the function of angiogenic factors such as VEGF, PDGF, and FGF. It has been shown to have anti-angiogenic effects in animal models of solid tumours. ZD-4190 also inhibits the integrin receptor which mediates the uptake of these molecules by endothelial cells and promotes angiogenesis. This agent inhibits hydrogen bonding between the VEGF molecule and its receptor at the cell surface, thereby preventing activation of the angiogenic process. The microvessel density was significantly reduced in animals treated with ZD-4190, suggesting a reduction in tumor vascularization.

Formula: C₁₉H₁₆BrFN₆O₂

Purity: Min. 95%

Molecular weight: 459.27 g/mol

Ref: 3D-NRA59962